Emergent BioSolutions Inc.
EBS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001367644
In the last 90 days, Emergent BioSolutions Inc. insiders filed 0 open-market purchases and 1 sale; 194 institutions reported holding it in 13F filings for Q2 2026, worth $373.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $25.2K in total
- 1
- 13F holdersQ2 2026, +6 vs. previous quarter
- 194
- 13F valueReported value at the end of Q2 2026
- $373.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding EBS, Q2 2026
No superinvestor reported holding EBS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Emergent BioSolutions Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 (view filing)12:57 PM ET | Jul 1 | 1 day | Williams Paul AnthonySVP, Products Business | SSale | −3.00K | $8.40 | −$25.2K | −1.9%159.1K after | 10b5-1 |
| May 4, 2026 (view filing) | May 1 | 3 days | Zoon Kathryn CDirector | SSale | −17.2K | $8.40 | −$144.5K | −17.7%79.9K after | 2 lots10b5-1 |
| May 4, 2026 (view filing) | May 1 | 3 days | DeGolyer Donald WDirector | SSale | −15.5K | $8.40 | −$130.0K | −10.7%129.7K after | 2 lots10b5-1 |
| May 4, 2026 (view filing) | May 1 | 3 days | Dayal Sujata TyagiDirector | SSale | −13.8K | $8.40 | −$115.6K | −12.0%100.6K after | 2 lots10b5-1 |
| May 4, 2026 (view filing) | Apr 30 | 4 days | Katkin KeithDirector | SSale | −15.5K | $8.28 | −$128.2K | −13.9%96.3K after | 10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Williams Paul AnthonySVP, Products Business | SSale | −4.00K | $8.44 | −$33.8K | −6.0%62.7K after | 10b5-1 |
| Dec 9, 2025 (view filing) | Dec 5 | 4 days | Richard RonaldDirector | SSale | −22.0K | $11.97 | −$263.1K | −18.3%98.4K after | 2 lots |
| Nov 12, 2025 (view filing) | Nov 10 | 2 days | DeGolyer Donald WDirector | SSale | −17.8K | $10.54 | −$187.6K | −12.9%119.9K after | |
| Nov 10, 2025 (view filing) | Nov 7 | 3 days | Dayal Sujata TyagiDirector | SSale | −8.55K | $10.00 | −$85.5K | −8.8%89.0K after | |
| Oct 16, 2025 (view filing) | Oct 7 | 9 daysLate | Glessner ColeenEVP, Quality & Ethics, and CPL | SSale | −30.6K | $10.00 | −$306.1K | −17.5%144.3K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Emergent BioSolutions Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,716,599 | $39.5M | 0.00% | +375,137+8.6% | Added |
| Dimensional Fund Advisors LP | 3,076,646 | $25.8M | 0.00% | +319,488+11.6% | Added |
| State Street Corp | 2,929,238 | $24.6M | 0.00% | +79,537+2.8% | Added |
| American Century Companies Inc | 2,770,448 | $23.2M | 0.01% | +344,726+14.2% | Added |
| Vanguard Capital Management LLC | 2,198,839 | $18.4M | 0.00% | −59,156−2.6% | Reduced |
| LSV Asset Management | 1,695,851 | $14.2M | 0.03% | +799,151+89.1% | Added |
| Acadian Asset Management LLC | 1,344,323 | $11.3M | 0.01% | −37,301−2.7% | Reduced |
| Geode Capital Management, LLC | 1,337,243 | $11.2M | 0.00% | +64,334+5.1% | Added |
| Charles Schwab Investment Management Inc | 1,200,791 | $10.1M | 0.00% | −305,284−20.3% | Reduced |
| Oak Hill Advisors LP | 1,113,338 | $9.33M | 1.33% | 00.0% | Unchanged |